Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Opdivo Disappoints in 1st-Line Lung Cancer Trial
August 9, 2016
- Carna Biosciences, Janssen Call Off Licensing Deal for Kinase Inhibitor
August 8, 2016
- Takeda, Pfizer to Wind Up Sales Deal for Prevenar, BeneFIX
August 8, 2016
- Meiji Seika Pharma Licenses Therapeutic Candidate Substance for Multiple Sclerosis to Curadim Pharma
August 8, 2016
- Astellas to Transfer US Manufacturing Unit to Avara
August 5, 2016
- Sumitomo Dainippon to Nurture Specialized Reps as It Pushes Oncology, Other Biz Focus
August 5, 2016
- Rohto, Osaka Univ. Tie Up for Stem Cell Research, Aim for Approval of Regenerative Medicine Products
August 5, 2016
- Zafatek Most Heavily Promoted Drug in GP Market in June: Anterio
August 4, 2016
- Teijin Jettisons Extended-Release Version of Feburic; Successor Now in PI
August 3, 2016
- Mitsubishi Tanabe Erases Alzheimer’s Drug from Japan Pipeline
August 3, 2016
- Adcetris Shows Positive Efficacy Profile in Cutaneous T-Cell Lymphoma
August 3, 2016
- Takeda’s Cx601 Stem Cell Therapy Hits Primary Endpoint in Global PIII
August 3, 2016
- Shionogi to Transfer 21 Off-Patent Products to Kyowa Pharm
August 3, 2016
- Opdivo Hauls in 25.2 Billion Yen in April-June
August 3, 2016
- Nichi-Iko Launches Tender Offer for Sagent
August 3, 2016
- Japan Market Grows in April-June on Hep C Meds, Opdivo: IMS
August 2, 2016
- Gil Feldman Picked as President of Teva API Japan
August 2, 2016
- Halaven Extends Duration of Response in Soft Tissue Sarcoma: Global PIII
August 2, 2016
- Sunovion Submits US NDA for COPD Drug
August 2, 2016
- Positive Changes Seen in Oncology R&D under New Head: Daiichi Sankyo CEO
August 2, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…